GlaxoSmithKline's combination benign prostatic hyperplasia (BPH) drug Combodart (dutasteride 0.5mg/tamsulosin hydrochloride 0.4mg) has been launched in the UK, its first market.
GlaxoSmithKline's combination benign prostatic hyperplasia (BPH) drug Combodart (dutasteride 0.5mg/tamsulosin hydrochloride 0.4mg) has been launched in the UK, its first market.
The once-daily pill combines GSK's 5-alpha reductase inhibitor Avodart (dutasteride), which was launched in the UK in 2003, with the...
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
Multi-blockbuster falls short in a giant cell arteritis study.
